Discover investment opportunities in Diabetes Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Diabetes Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Diabetes Stocks using our Smart AI Filter.
10 stocks found for "Diabetes Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.49 | ±19.6% | 26.1 | 1.76% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
0.80 | ±35.4% | 77.8 | 0.00% | |||
1.02 | ±49.1% | 40.9 | 0.00% | |||
0.76 | ±41.4% | 25.6 | 0.00% | |||
1.50 | ±76.4% | -13.9 | 0.00% | |||
0.59 | ±31.6% | 34.5 | 0.77% | |||
2.07 | ±100.0% | -4.2 | 0.00% | |||
0.33 | ±27.9% | 8.6 | 4.00% | |||
0.72 | ±40.2% | 17.0 | 3.18% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How do Eli Lilly (LLY) and Novo Nordisk (NVO) compare as diabetes-focused pharmaceutical companies?
A: Eli Lilly and Novo Nordisk are leaders in diabetes treatments, with strong portfolios in insulin and GLP-1 therapies. Eli Lilly has a diversified range of pharmaceuticals, while Novo Nordisk focuses predominantly on diabetes and obesity care. Market performance varies, reflecting differences in R&D investments and commercial strategies.
Q: What are the income potentials from diabetes-focused stocks like Sanofi (SANOFI) and Pfizer (PFE)?
A: Sanofi and Pfizer offer dividends, with yields affected by market conditions and financial performance. Sanofi's diverse product range may contribute to stable dividends, while Pfizer, though diversified, faces income variability due to patent expirations and competition.
Q: How might continuous glucose monitoring companies like Dexcom (DXCM) and Insulet (PODD) benefit from technological advancements?
A: Dexcom and Insulet, leaders in CGM technology, may benefit from increasing demand for real-time diabetes management solutions. Technological advancements in sensor accuracy and connectivity can enhance these products' appeal and market share.
Q: What sector-specific risks do Medtronic (MDT) and MannKind (MNKD) face in the diabetes space?
A: Medtronic, a diversified medical technology company, faces regulatory and competition risks. MannKind, focused on innovative diabetes therapies, encounters high R&D costs and market adoption challenges. Both companies must navigate evolving healthcare regulations.
Q: How do the growth prospects of Vertex Pharmaceuticals (VRTX) differ from typical diabetes stocks?
A: Vertex primarily focuses on cystic fibrosis, with emerging efforts in diabetes through gene-editing technologies. Compared to traditional diabetes stocks, Vertex’s growth outlook hinges on its ability to diversify into innovative areas like regenerative medicine.
Q: Can investors expect stability from diabetes treatment stocks considering economic cycles?
A: Diabetes treatment stocks like Eli Lilly and Novo Nordisk generally show resilience due to the consistent demand for chronic disease management. However, market volatility and healthcare policy changes may pose challenges to stability in economic downturns.